Syra Health Corp. Class A Common Stock (SYRA) Financial Ratios
6 years of historical data (2020–2025) · Healthcare · Medical - Care Facilities
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
2.83
↑+207% vs avg
5yr avg: 0.92
30Y Low0.5·High1.2
ROE
↑
-36.0%
↓+83% vs avg
5yr avg: -218.0%
30Y Low-124%·High-36%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
SYRA Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Syra Health Corp. Class A Common Stock currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Market Cap | $6M | $1M | $3M | $5M | — | — | — |
| Enterprise Value | $4M | $-451644 | $1M | $2M | — | — | — |
| P/E Ratio → | -6.62 | — | — | — | — | — | — |
| P/S Ratio | 0.79 | 0.14 | 0.37 | 0.90 | — | — | — |
| P/B Ratio | 2.83 | 0.49 | 1.04 | 1.23 | — | — | — |
| P/FCF | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
SYRA EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | -0.06 | 0.13 | 0.35 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — |
SYRA Profitability
Margins and return-on-capital ratios measuring operating efficiency
Syra Health Corp. Class A Common Stock earns an operating margin of -12.5%. Operating margins have expanded from -52.4% to -12.5% over the past 3 years, signaling improving operational efficiency. A negative ROE of -36.0% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Gross Margin | 34.4% | 34.4% | 20.7% | 25.5% | 18.9% | 30.5% | — |
| Operating Margin | -12.5% | -12.5% | -47.2% | -52.4% | -37.2% | -0.2% | — |
| Net Profit Margin | -12.4% | -12.4% | -47.1% | -53.3% | -37.7% | -0.2% | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| ROE | -36.0% | -36.0% | -109.1% | -124.4% | -602.6% | — | — |
| ROA | -27.8% | -27.8% | -87.4% | -81.1% | -148.3% | -1.2% | -142.2% |
| ROIC | -86.8% | -86.8% | -294.7% | -165.1% | -167.0% | -2.1% | — |
| ROCE | -35.0% | -35.0% | -106.4% | -120.7% | -487.2% | -8.2% | — |
SYRA Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $2M exceeds total debt of $143787, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.07 | 0.07 | 0.16 | 0.06 | 1.32 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.70 | -0.68 | -0.76 | 1.31 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — |
| Interest Coverage | -68.15 | -68.15 | -239.98 | -53.73 | -73.24 | — | — |
Net cash position: cash ($2M) exceeds total debt ($143787)
SYRA Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Syra Health Corp. Class A Common Stock's current ratio of 4.06x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 5.25x to 4.06x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 4.06 | 4.06 | 5.46 | 5.25 | 0.92 | 0.84 | 0.42 |
| Quick Ratio | 4.06 | 4.06 | 5.46 | 5.25 | 0.89 | 0.84 | 0.42 |
| Cash Ratio | 2.39 | 2.39 | 3.90 | 3.60 | 0.00 | 0.22 | 0.42 |
| Asset Turnover | — | 2.61 | 2.17 | 1.12 | 2.42 | 2.63 | — |
| Inventory Turnover | — | — | — | — | 96.51 | — | — |
| Days Sales Outstanding | — | 46.39 | 31.13 | 78.38 | 87.47 | 73.04 | — |
SYRA Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Syra Health Corp. Class A Common Stock does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $12M | $7M | $5M | $7M | $7M | $6M |
Peer Comparison
Compare SYRA with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 SYRAYou | $6M | -6.6 | — | — | 34.4% | -12.5% | -36.0% | -86.8% | — |
 TALK | $868M | 129.5 | 137.8 | — | 43.0% | 1.4% | 6.6% | 3.9% | — |
 ACMR | $4B | 43.2 | 27.5 | — | 44.4% | 12.1% | 6.2% | 7.0% | 2.4 |
 CLOV | $1B | -16.6 | — | — | 18.5% | -4.4% | -26.3% | -34.0% | — |
 LFMD | $215M | -19.5 | — | 33.6 | 79.8% | -4.0% | -74.4% | — | — |
 OPRX | $124M | 24.6 | 6.5 | 6.6 | 67.3% | 10.7% | 4.2% | 7.1% | 0.3 |
 DOCS | $5B | 23.5 | 21.1 | 19.6 | 90.2% | 39.9% | 22.5% | 20.0% | 0.1 |
 HIMS | $7B | 50.3 | 42.7 | 89.6 | 59.3% | 5.2% | 25.2% | 10.7% | 6.4 |
 TDOC | $1B | -6.1 | 15.1 | 4.4 | 69.5% | -10.4% | -13.9% | -11.5% | 10.4 |
 AMWL | $129M | -1.3 | — | — | 53.3% | -42.2% | -33.9% | -95.1% | — |
 GDRX | $973M | 33.3 | 4.0 | 5.9 | 82.1% | 13.4% | 4.5% | 13.0% | 0.3 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 6 years · Updated daily
See SYRA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SYRA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SYRA vs TALK
Side-by-side business, growth, and profitability comparison vs Talkspace, Inc..
Start ComparisonSYRA — Frequently Asked Questions
Quick answers to the most common questions about buying SYRA stock.
What is Syra Health Corp. Class A Common Stock's P/E ratio?
Syra Health Corp. Class A Common Stock's current P/E ratio is -6.6x. This places it at the 50th percentile of its historical range.
What is Syra Health Corp. Class A Common Stock's ROE?
Syra Health Corp. Class A Common Stock's return on equity (ROE) is -36.0%. The historical average is -89.8%.
Is SYRA stock overvalued?
Based on historical data, Syra Health Corp. Class A Common Stock is trading at a P/E of -6.6x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Syra Health Corp. Class A Common Stock's profit margins?
Syra Health Corp. Class A Common Stock has 34.4% gross margin and -12.5% operating margin.